Position paper: imaging methods for primary renal tumors of childhood: costs versus benefits.
The patterns of disease distribution at diagnosis and during follow-up were cataloged for the primary renal tumors of childhood. These data, derived from more than 1,500 patients, were used to define the most rewarding and cost-effective imaging methods required for patient management. The basic information needed prior to surgery includes whether there is a functioning kidney on the opposite side, and whether there are lung metastases or inferior vena cava thrombi. Simple X-ray examinations and ultrasonography (US) will provide the necessary data. Postoperatively, when the histology is known, examination of the brain (MRI or CT scan) is needed for patients with the rhabdoid tumor and clear cell sarcoma of the kidney (CCSK) who are prone to develop brain lesions; and the skeletal system (bone scan, X-ray skeletal survey) for CCSK and for renal cell carcinoma patients who tend to develop bone metastases. Continuing examination of the lung (chest films) is required for all histologies except perhaps for mesoblastic nephroma, which seldom metastasizes. The opposite kidney needs follow-up (US) for 5 or more years to exclude metachronous involvement if nephrogenic rests are present in either kidney. Sophisticated imaging studies, which cost five times or more than simple X-ray examinations or US, are not warranted routinely, and should be reserved for those cases where simpler, less expensive studies do not suffice for reaching patient management decisions.
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia 19104.
G J
GJ
D'Angio
H
H
Rosenberg
K
K
Sharples
P
P
Kelalis
N
N
Breslow
D M
DM
Green
D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary; D001932:Brain Neoplasms / Q000175:diagnosis / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000473:pathology / Q000556:secondary; D002648:Child; D003362:Cost-Benefit Analysis; D003952:Diagnostic Imaging / Q000191:economics*; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000473:pathology; D008175:Lung Neoplasms / Q000175:diagnosis / Q000556:secondary; D009364:Neoplasm Recurrence, Local; D012509:Sarcoma / Q000175:diagnosis / Q000473:pathology / Q000556:secondary; D015996:Survival Rate; D009396:Wilms Tumor / Q000175:diagnosis / Q000473:pathology / Q000556:secondary